Acumen Pharmaceuticals (Nasdaq: ABOS) has exercised its exclusive option under its collaboration with Japan-based JCR Pharmaceuticals Co., Ltd. (TSE: 4552), converting a research-stage partnership into a full global license to develop up to two Alzheimer's disease candidates using JCR's J-Brain Cargo technology. The move puts the Enhanced Brain Delivery program on a path toward an IND filing in mid-2027 while giving Acumen global rights to next-generation, blood-brain barrier-penetrating anti-amyloid antibody candidates.
Under the terms of the agreement, JCR will receive an option exercise payment — the amount of which was not disclosed — along with up to USD 40 million in development milestones and up to USD 515 million in sales milestones, for a total potential value of up to USD 555 million (approximately JPY 83.2 billion at JPY 150 per USD). JCR is also entitled to tiered royalties on net sales of any products that emerge from the collaboration. Acumen holds global rights to develop, manufacture, and commercialize up to two candidates. The option exercise closes out the research phase of a collaboration first announced in July 2025, during which Acumen raised USD 35.75 million in March 2026 specifically to fund preclinical development of the Enhanced Brain Delivery program.
The program pairs Acumen's sabirnetug (ACU193) — a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβOs) rather than amyloid plaques — with JCR's J-Brain Cargo platform, described by JCR as a transferrin receptor-targeting technology that shuttles biologics across the blood-brain barrier via receptor-mediated transcytosis. The resulting conjugated candidates, designated ACU301 and ACU401, are intended to achieve substantially higher brain exposure than unmodified antibodies. Preclinical data presented at the AD/PD 2026 conference in March 2026 showed that EBD candidates achieved 14- to 40-fold higher brain levels in non-human primates compared with native antibodies at 24 hours, with hematology data indicating low anemia risk — a key safety concern with transferrin receptor-targeting approaches — and stability profiles supporting subcutaneous administration.
J-Brain Cargo has one approved product, Izcargo (pabinafusp alfa), cleared in Japan in 2021 for Hunter syndrome (mucopolysaccharidosis type II) with CNS involvement, making it one of the few BBB-delivery platforms with a marketed product. Sabirnetug is currently being evaluated in the Phase II ALTITUDE-AD trial in early symptomatic Alzheimer's disease, following positive Phase I results in INTERCEPT-AD. The US FDA has granted sabirnetug Fast Track designation for early AD.